Insys Therapeutics to Present at 26th Annual Piper Jaffray Healthcare Conference

(firmenpresse) - PHOENIX, AZ -- (Marketwired) -- 11/19/14 -- Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference as follows:

Conference: Wednesday, December 3, 2014
Time: 11:30 a.m. EST
Location: The New York Palace, New York City

The presentation will be webcast live at the aforementioned time and simultaneously available via the link provided, as well as archived for 90 days thereafter, via the Company's website at , under the Investors Section.



Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, Subsys®, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules. The Company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. Insys is also developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 19.11.2014 - 21:30 Uhr
Sprache: Deutsch
News-ID 354097
Anzahl Zeichen: 0

contact information:
Town:

PHOENIX, AZ

Kategorie:

Drugs

Diese Pressemitteilung wurde bisher 208 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Insys Therapeutics to Present at 26th Annual Piper Jaffray Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Insys Therapeutics (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Insys Therapeutics Announces Its Naloxone Sublingual Spray Received Fast Track D ...

PHOENIX, AZ -- (Marketwired) -- 10/29/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to its ...

Insys Therapeutics Issues Statement on Its Use of Specialty Pharmacies ...

PHOENIX, AZ -- (Marketwired) -- 10/26/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today issued a statement on the Company's use of specialty pharmacies:Insys distributes Subsys through both speci ...

Insys Therapeutics to Report Third Quarter 2015 Results ...

PHOENIX, AZ -- (Marketwired) -- 10/22/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will release its financial results for the third quarter 2015 on Thursday, November 5, 2015, before the U.S. financial markets open. ...

Alle Meldungen von Insys Therapeutics